Agenus Q2 Revenue Jumps on Royalty and Access Income, Operating Income Hits $11.3M
AGEN has more than doubled off its 52-week low of $2.71 on light trading volume (0.4× avg).
Summary
Agenus reported Q2 revenue growth driven by higher royalty and access program income, with operating income reaching $11.3 million. Broader BOT+BAL access programs across more countries contributed $6.4 million in pre-commercial product revenue. The company also highlighted disciplined cost management and resource prioritization for the pivotal Phase 3 ROBBIN trial. This follows the $85 million private placement completed after quarter-end, which is expected to fund operations through Q3 2027, with warrants potentially extending runway to 2031. The results show continued financial improvement after the strong Q1 turnaround and closure of the SEC investigation in May.
At the time of this announcement, AGEN was trading at $7.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $348.2M. The 52-week trading range was $2.71 to $8.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.